Oncimmune Holdings PLC EarlyCDT®-Lung Kit Distribution Agreements
September 19 2017 - 2:01AM
RNS Non-Regulatory
TIDMONC
Oncimmune Holdings PLC
19 September 2017
19 September 2017
Oncimmune Holdings plc
("Oncimmune" or the "Company")
First Distribution Agreements Signed for EarlyCDT(R)-Lung Kit in
Europe
Exclusive agreements for Denmark, Norway and Sweden with
aggregate minimum sales commitment of approximately GBP500,000
Nottingham, UK - 19 September 2017: Oncimmune Holdings plc (AIM:
ONC.L), a leading early cancer detection company developing and
commercialising its proprietary EarlyCDT(R) platform technology,
today announces it has signed three new exclusive distribution
agreements for its EarlyCDT(R)- Lung test with LabLab ApS, Diuvita
Diagnostics AS and XboXLab AB in Denmark, Norway and Sweden
respectively.
The agreements allow for the sale of the CE marked kit to local
laboratories and as a central laboratory test. The three agreements
are for an initial term of three years and include minimum sales
commitments of approximately GBP500,000. First sales are expected
to commence late in 2017/early 2018.
Geoffrey Hamilton-Fairley, CEO of Oncimmune, commented: "These
distribution agreements, which we anticipate to be the first of
many across Europe, give us full coverage of the Scandinavian
region where we have received a great deal of interest in our
EarlyCDT(R)-Lung test. As part of the strategy indicated at the
time of our IPO, we outlined our plan to grow into multiple regions
with multiple products and these latest agreements not only show
our commitment to that strategy but also indicate the strength and
potential of our EarlyCDT(R)-Lung test and kit."
For further information:
Oncimmune Holdings plc
Geoffrey Hamilton-Fairley, Chief Executive Officer
contact@oncimmune.co.uk
Zeus Capital Limited
Phil Walker, Giles Balleny, Hugh Kingsmill Moore
+44 (0) 203 829 5000
Media enquiries:
Consilium Strategic Communications
Chris Gardner, Matthew Neal, Lindsey Neville
oncimmune@consilium-comms.com
+44 (0) 20 3709 5708
About Oncimmune
Oncimmune is a leading early cancer detection company developing
and commercialising its proprietary EarlyCDT(R) platform
technology. Oncimmune has pioneered the development of autoantibody
tests that can detect cancer up to four years earlier than other
methods and can be applied to a very wide range of solid tumour
types. The Company's first product, EarlyCDT(R)-Lung, was launched
in 2012, as a CLIA test in the USA and since then over 150,000
commercial tests have been sold. EarlyCDT(R)-Lung is available
through physicians in the US and also privately in the UK and other
regions. EarlyCDT(R)-Lung is being used in the largest ever
randomised trial for the early detection of lung cancer using
biomarkers. The NHS Scotland ECLS study of over 12,000 high-risk
smokers is now fully recruited and in the final follow up stage.
EarlyCDT(R) tests for liver and ovarian cancer are in
development.
Oncimmune, headquartered in Nottingham, United Kingdom with
testing facilities in the US, joined AIM in May 2016 under the
ticker ONC.L. For more information visit www.oncimmune.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAOKFDQKBKBOCD
(END) Dow Jones Newswires
September 19, 2017 02:01 ET (06:01 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2023 to Apr 2024